Mallinckrodt Breached Pain Med Licensing Deal, Nuvo Says

Law360, New York (August 21, 2013, 3:41 PM ET) -- Drug giant Mallinckrodt Inc. was sued on Tuesday by pain medication firm Nuvo Research Inc., which accuses it of jeopardizing the approval prospects of Nuvo drug Pennsaid Plus and breaching a licensing deal through "regulatory gambles" that include failing to finish necessary clinical trials. 

In a complaint filed in New York federal court, Nuvo claimed that Mallinckrodt had backed out of requirements under its licensing agreement for Nuvo's “most promising pharmaceutical asset” by failing to finish certain mandatory trials and mismanaging studies it was supposed to...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required